ISRG

Meta, SpaceX, and Tesla posted strong revenue but are spending heavily on AI infrastructure with uncertain cash flow outcomes. Walmart opened AI shopping to approved agents while Amazon blocked them.

Salesforce acquired Braze for a 58% premium but analysts expect modest returns. Netflix and Intuitive Surgical face pricing power challenges. Old-economy companies like Cisco, Corning, and EQT benefit from AI buildout demand.

Five stocks were added to the Zacks Rank #1 (Strong Buy) list today. Universal Insurance Holdings showed the strongest earnings estimate growth at 26.4% over 60 days, while Hasbro, Texas Instruments, United Rentals, and Intuitive Surgical showed more modest earnings estimate increases ranging from 0.3% to 1.9%.

Cathie Wood's Ark Invest added to positions in Netflix, Oklo, and Intuitive Surgical on Wednesday, all of which have declined significantly over the past year. Netflix hit a two-year low after disappointing guidance, Oklo has surrendered 86% from its peak despite promising nuclear technology, and Intuitive Surgical faces competitive threats but maintains strong earnings beats.

Intuitive Surgical reported Q3 2026 earnings beating consensus estimates with $3.05B in revenue. The company announced planned instrument pricing reductions of 3-5% to expand robotic surgery adoption, narrowed 2026 procedure growth guidance to 14-15%, and raised gross margin outlook to 68.7-69.3%. U.S. procedure growth slowed to 10% while international placements surged 29%, with strong expansion in Europe and Asia.

Salesforce acquires Braze for $5.7 billion to strengthen its marketing capabilities, with Braze stock jumping 50%. Netflix faces growth challenges with slowing revenue and weak ad performance.

SpaceX beats expectations with 161% revenue growth, while Intuitive Surgical falls despite beating estimates due to cooling U.S. procedure growth. Tesla, Meta, and IBM report earnings with major capital spending decisions in focus. EQT continues steady cash flow growth as a natural gas producer.

Intuitive Surgical reported Q3 2026 revenue of $3.05 billion, up 21.7% year-over-year, beating the consensus estimate of $2.88 billion by 5.84%. EPS came in at $3.00, exceeding the estimate of $2.61 by 14.94%.

Key metrics including system placements (546 vs. 475 estimated) and revenue across all segments outperformed analyst expectations. The stock has gained 7.9% over the past month and holds a Zacks Rank #2 (Buy) rating.

Stock futures opened lower as investors await economic data and earnings reports. The housing market continues to struggle with September Housing Starts and Building Permits missing expectations, driven by elevated mortgage rates.

GE and GM both beat Q3 earnings estimates, though GM's downward guidance weighed on shares. Netflix, United Airlines, and Intuitive Surgical are set to report earnings today.

Stock futures opened lower on October 20, 2026, driven by rising oil prices amid geopolitical tensions in the Strait of Hormuz. September housing data disappointed with starts and permits both declining, reflecting weakness in the real estate market due to elevated mortgage rates.

GE and GM beat Q3 earnings expectations, though GM's downward guidance pressured shares. Netflix, United Airlines, and Intuitive Surgical are set to report earnings after market close.

Three Wall Street analysts have $500 price targets for Intuitive Surgical, citing strong growth in robot-assisted surgery procedures and the rollout of the da Vinci 5 platform. The company benefits from a recurring revenue model through instruments and accessories, with procedures growing 15% year-over-year. However, the stock's high P/E ratio of ~49 leaves limited room for disappointment.

Intuitive Surgical (ISRG), the leader in surgical robotics, has fallen 30% from early 2025 highs but presents a strong buy opportunity with ~40% upside potential. The company demonstrates impressive fundamentals including double-digit earnings and revenue growth, a debt-free balance sheet, and strong free cash flow expansion. ISRG earned a Zacks Rank #2 (Buy) rating and is positioned for a technical breakout ahead of Q3 earnings.

Intuitive Surgical, the leader in surgical robotics, has fallen 30% from early 2025 highs but is poised for a technical breakout ahead of its Q3 earnings release on October 20. With strong fundamentals including double-digit earnings and revenue growth, a debt-free balance sheet, and ~43% upside potential to all-time highs, the stock earns a Zacks Rank #2 (Buy) rating. The company projects 15% Q3 revenue growth and 17% revenue growth for 2026.

Intuitive Surgical (ISRG) is expected to report Q3 2026 earnings on October 20 with EPS projected at $2.61 (up 8.75%) and revenue growth of 15% to $2.88B. While the company benefits from international procedure growth and strong da Vinci 5 demand, it faces headwinds from moderating U.S. procedure growth, China pricing pressures, and higher costs. The stock trades at a premium valuation of 35.87X forward P/E, leaving limited room for disappointment.

Intuitive Surgical (ISRG) outperformed the broader market on October 15, 2026, closing up 1.81% and gaining 9.93% over the past month. The company has a Zacks Rank #2 (Buy) rating with expected Q3 EPS growth of 8.75% and full-year earnings growth of 20.27%. However, the stock trades at a premium valuation with a Forward P/E of 39.15 compared to the industry average of 23.25.

Intuitive Surgical (ISRG) has gained nearly 12% in a month, outperforming the market ahead of Q3 earnings. The company benefits from strong da Vinci 5 adoption, growing Ion procedures, and expanding international markets.

However, slower U.S. procedure growth, GLP-1 drug competition affecting bariatric procedures, and China headwinds pose risks. ISRG trades at a premium 36.04X forward P/E but remains attractive with a Zacks Rank #2 (Buy) rating.

Intuitive Surgical submitted a next-generation flexible robotic endoscope to the FDA for 510(k) clearance, marking expansion into gastrointestinal care. The platform combines expertise from da Vinci surgical systems and Ion lung biopsy platform but remains in early development with no near-term revenue expected. Success will depend on regulatory approval, clinical evidence, and physician adoption.

Intuitive Surgical (ISRG) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 remains at $10.74 per share, with analysts raising estimates by 3.5% over the past three months. The upgrade positions ISRG in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals.

Intuitive Surgical (ISRG) has been heavily searched on Zacks.com and has outperformed the broader market with a +13.2% return over the past month. The company holds a Zacks Rank #2 (Buy) rating based on strong earnings estimate trends, with expected earnings growth of +20.3% for the current fiscal year and +11.6% for the next year.

Revenue is projected to grow +16.7% and +12.5% respectively. However, the stock trades at a premium valuation (D grade) compared to peers.

Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield.

Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors.

The article recommends four healthcare stocks across two key niches: GLP-1 weight-loss drugs (Eli Lilly and Novo Nordisk) and surgical robotics (Intuitive Surgical and Medtronic). Eli Lilly leads in GLP-1 but faces patent expiration risks, while Novo Nordisk is a turnaround story with attractive valuation. Intuitive Surgical dominates surgical robotics with strong recurring revenue, while Medtronic offers a diversified play with dividend appeal as it launches its Hugo surgical robot.

Intuitive Surgical (ISRG) outperformed the S&P 500 with a +2.06% daily gain, reaching $423.96. The stock has gained 15.24% prior to trading and is expected to report Q3 earnings on October 20, 2026, with forecasted EPS of $2.61 (+8.75% YoY) and revenue of $2.88 billion (+14.98% YoY). However, the stock trades at a premium valuation with a Forward P/E of 38.7 versus the industry average of 22.63, and holds a Zacks Rank of #3 (Hold).